Literature DB >> 28648493

The use of fructosamine in cystic fibrosis-related diabetes (CFRD) screening.

Grace Y Lam1, Michelle Doll-Shankaruk2, Jan Dayton3, Karina Rodriguez-Capote4, Trefor N Higgins4, Dylan Thomas4, Kimberley Mulchey5, Maeve P Smith5, Neil E Brown5, Winnie M Leung5, Mathew P Estey6.   

Abstract

OBJECTIVE: To determine whether serum fructosamine correlates with glycemic control and clinical outcomes in patients being screened for cystic fibrosis-related diabetes (CFRD).
METHODS: Fructosamine and percent predicted forced expiratory volume in 1s (FEV1) were measured in patients undergoing a 2h oral glucose tolerance test (OGTT) for CFRD screening. Fractional serum fructosamine (FSF) was calculated as fructosamine/total protein.
RESULTS: FSF exhibited a positive correlation with 2h OGTT results (r2=0.3201, p=0.009), and ROC curve analysis suggested that FSF can identify patients with an abnormal OGTT (AUC=0.840, p=0.0002). FSF also exhibited a negative correlation with FEV1 (r2=0.3732, p=0.035). Patients with FSF≥3.70μmol/g had significantly lower FEV1 (median 47%) compared to those with FSF<3.70μmol/g (median 90%; p=0.015).
CONCLUSIONS: FSF correlated with both OGTT results and FEV1, and reliably identified patients with abnormal OGTT results. This simple blood test shows potential as an effective tool in CFRD screening.
Copyright © 2017 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cystic fibrosis-related diabetes; FEV(1); Oral glucose tolerance test; Screening; Serum fructosamine

Mesh:

Substances:

Year:  2017        PMID: 28648493     DOI: 10.1016/j.jcf.2017.05.010

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  3 in total

1.  Hemoglobin A1c and fructosamine correlate in a patient with sickle cell disease and diabetes on chronic transfusion therapy.

Authors:  Ashley McLean; Frances Wright; Neal deJong; Sarah Skinner; Ceila E Loughlin; Amy Levenson; Marcus A Carden
Journal:  Pediatr Blood Cancer       Date:  2020-07-03       Impact factor: 3.167

2.  Cystic fibrosis-related diabetes: Prevalence, screening, and diagnosis.

Authors:  Swapnil Khare; Marisa Desimone; Nader Kasim; Christine L Chan
Journal:  J Clin Transl Endocrinol       Date:  2021-12-07

Review 3.  Screening Methods for Diagnosing Cystic Fibrosis-Related Diabetes: A Network Meta-Analysis of Diagnostic Accuracy Studies.

Authors:  Vera Dóra Izsák; Alexandra Soós; Zsolt Szakács; Péter Hegyi; Márk Félix Juhász; Orsolya Varannai; Ágnes Rita Martonosi; Mária Földi; Alexandra Kozma; Zsolt Vajda; James Am Shaw; Andrea Párniczky
Journal:  Biomolecules       Date:  2021-03-31
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.